Consider a long position in Eli Lilly (LLY), which is showing exceptional growth driven by its blockbuster drugs Mounjaro and Zepbound. A strong bearish view is held on the Quantum Computing sector, which is seen as overhyped and facing a potential collapse as AI proves to be a more practical alternative. A high-conviction short position is active on Capper, with the expectation that the company's value will go to zero. Investors should avoid Ovid Therapeutics (OVID) ahead of its upcoming data release for OV329, which is viewed as a high-risk binary event with a low probability of success. This analysis suggests the technology behind quantum stocks is not living up to its promises, making the entire sector a potential short.

Quantum Computing (Sector)

• The speaker, Martin Shkreli, expresses a strong bearish sentiment on the quantum computing sector, stating, "Top is in for sure" and "Quantum funny games is over."
• He references a video by physicist Sabine Hossenfelder, who argues the sector is "hugely overhyped" and predicts that most commercial interest will "just collapse" in the next few years.
• The discussion highlights that while quantum computers have potential applications in decryption, chemistry, logistics, and asset management, there are very few proven algorithms that offer a real advantage over conventional computers.
• A key point made is that Artificial Intelligence (AI) is already solving many of the problems that quantum computing aims to address, particularly in quantum chemistry and materials science.
• Shkreli analyzes a research paper from HSBC and IBM on using quantum computing for bond trading. He concludes the paper is "100% bullshit" due to a logical flaw:
  • The experiment showed that the real quantum hardware (which has inherent errors or "noise") performed better than a "noiseless quantum simulator" (a perfect, simulated version).
  • Shkreli argues this is impossible, as a perfect system cannot be outperformed by an identical but flawed one. He states, "The quantum hardware has noise. It can't be better." This suggests the positive results are not credible.

Takeaways

• Sentiment is highly negative. The speakers believe the hype around quantum computing has peaked, and the sector is poised for a downturn as commercial applications fail to materialize.
• Consider shorting or avoiding quantum stocks. Shkreli's analysis implies that the technology is not living up to its promises and that positive news (like the HSBC paper) may be flawed or misleading.
• AI is a competing technology. Investors should be aware that advancements in AI may make quantum computing redundant for some of its most-touted applications.

Eli Lilly and Company (LLY)

• The podcast features a presentation from Lilly's CFO, Lucas Montas, at a Bernstein conference, which provides a very bullish outlook for the company.
• Exceptional Revenue Growth: Revenue grew 38% in the second quarter and 40% in the first half of the year, significantly outpacing the pharmaceutical industry.
• Dominant Key Products:
  • The company's blockbuster drug, Tirzepatide, sold under the names Mounjaro (for diabetes) and Zepbound (for weight loss), is leading the charge.
  • The portfolio of key growth products generated over $10 billion in the second quarter alone, growing at 80%.
• Manufacturing and Supply Chain Strength:
  • Lilly has resolved the previous shortage of Tirzepatide and is aggressively ramping up production, with a goal to increase output by 1.8 times in the second half of the year.
  • The company is making major long-term investments in new US-based manufacturing sites to ensure supply resiliency for the next 15-20 years.
• Robust R&D Pipeline: Lilly has promising drugs in development across several areas:
  • Oncology: Imlunestran, an oral drug, is expected to launch next year.
  • Neuroscience: Donanemab for Alzheimer's disease represents a significant future opportunity.
• Financial Discipline: Despite massive growth, the company is maintaining a relatively flat headcount (outside of manufacturing) by leveraging AI and automation, demonstrating operational efficiency.

Takeaways

• Strong Bullish Case: The presentation paints a picture of a company firing on all cylinders, with massive revenue growth, a blockbuster drug franchise, a strong pipeline, and a well-managed manufacturing expansion.
• Long-Term Growth Potential: Lilly is not just focused on the short term; it is making strategic investments in manufacturing and R&D to support growth for the next decade and beyond.
• Key Growth Drivers: Investors should monitor the sales of Mounjaro and Zepbound, as well as progress on pipeline drugs like Imlunestran and Donanemab, as these are central to the company's future success.

Ovid Therapeutics (OVID)

• Shkreli expresses a bearish and dismissive view of the company, calling it a "crappy drug company."
• He notes an upcoming catalyst: results for the drug OV329 in a study with healthy volunteers.
• He calls this a "binary event" but believes the data will likely be meaningless, stating it "doesn't look like there's going to be any data worth... sinking one's teeth into."
• He concludes that analyzing the company further is a "waste of time."

Takeaways

• High Risk, Low Confidence: The upcoming data for OV329 is a major risk event for the stock.
• Negative Outlook: The speaker has very low confidence in the company and the potential for its upcoming clinical trial results to be positive or meaningful.
• Avoid or Be Cautious: Based on this analysis, investors might consider avoiding the stock, especially ahead of the data release, due to the perceived high probability of failure.

Capper (No Ticker Provided)

• Shkreli's sentiment is extremely bearish.
• He explicitly states his position: "I'm short capper right now."
• He believes the company is destined to fail, stating, "it's obviously going to fail. Well, it literally can't work, I don't think." and "Capper is zero. We all know this."

Takeaways

• Extreme Bearish Conviction: The speaker has a very strong negative conviction on this investment.
• Actionable Short Position: This is a direct mention of a short position, indicating a belief that the value of the asset will go to zero.

OpenDoor (OPEN)

• This stock was mentioned briefly in the context of another firm's opinion.
• Shkreli states, "Jane Street is not bullish on open door."
• He qualifies this by adding that Jane Street (a quantitative trading firm) doesn't employ traditional stock analysts who predict price direction.

Takeaways

• Negative Data Point: The mention suggests that a major quantitative trading firm, Jane Street, does not have a positive view on the stock.
• Limited Insight: This is not a deep analysis but rather a passing comment on another firm's sentiment, which should be taken with a grain of salt.